- The binding site has grown significantly under the owners of Nordic Capital and Five Arrows, creating an industry leader in oncology testing for the detection and monitoring of multiple myeloma
STOCKHOLM, October 31, 2022 /PRNewswire/ — Nordic Capital and Five Arrows have Entered into a definitive agreement to sell The Binding Site, a global leader in specialty diagnostics, to Thermo Fisher Scientific, the world’s leading service provider for science. The transaction is rated with £2.25 billion. Since taking over The Binding Site in 2011, the company has completed an impressive transformation from a founder-led, research-based organization to a leading provider of innovative medical solutions that advance the detection, diagnosis and treatment of blood cancers and immune system disorders.
The transformation has been achieved through significant investment in its technology, growth and with a dedicated focus on research and development to support research and drive improved clinical outcomes. Since 2011, The Binding Site has grown five-fold, with sales of approximately £200m in 2022 and more than 40 million tests sold worldwide. The Binding Site’s Freelite® offering is widely recommended by many major publications on clinical diagnostic and treatment guidelines for the diagnosis and monitoring of multiple myeloma at multiple disease stages. By joining Thermo Fisher Scientific, the world leader in serving science, The Binding Site will be even better positioned to accelerate scientific discovery and expand its product offering.
“We are proud to have worked with The Binding Site. Its cutting-edge technology and innovative specialty diagnostic solutions improve the lives of millions of patients worldwide. During the ownership of Nordic Capital The company has experienced strong growth and transformation achieved through a dedicated focus on R&D investments, commercial alignment and global expansion. We are grateful to the team at The Binding Site for their dedication and for building strong…
